julian blagg

Azeria Therapeutics announces appointment of Dr Julian Blagg as VP Drug Discovery

Azeria Therapeutics, a newly formed drug discovery company, today announced the appointment of Dr Julian Blagg as VP Drug Discovery. Dr Blagg has over 30 years’ experience in medicinal chemistry and drug discovery; he was most recently Deputy Director and Head of Chemistry at The CRUK Cancer Therapeutics Unit at the Institute of Cancer Research.

Azeria Therapeutics, the world’s first pioneer factor drug discovery company, announces Series A investment from Sixth Element Capital

Azeria Therapeutics Limited, a newly formed drug discovery company, today announced that it has successfully raised £4 million in Series A fundraising from the £70 million CRT Pioneer Fund, managed by Sixth Element Capital LLP (6EC), a UK based fund manager.